Пређи на садржај

Fondaparinuks

С Википедије, слободне енциклопедије
Fondaparinuks
Klinički podaci
Drugs.comMonografija
Način primeneSubkutano
Farmakokinetički podaci
Poluvreme eliminacije17-21 h
IzlučivanjeRenalno
Identifikatori
CAS broj114870-03-0 Зелена квачицаДа
ATC kodB01AX05 (WHO)
PubChemCID 636380
DrugBankDB00569 Зелена квачицаДа
ChemSpider552174 Зелена квачицаДа
ChEBICHEBI:31632 Зелена квачицаДа
ChEMBLCHEMBL1201202 Зелена квачицаДа
Hemijski podaci
FormulaC31H45N3Na10O49S8
Molarna masa1730,097
  • [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].CO[C@H]1O[C@H](COS([O-])(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS([O-])(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS([O-])(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS([O-])(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS([O-])(=O)=O)[C@H]3NS([O-])(=O)=O)[C@H](O)[C@H]2OS([O-])(=O)=O)C(O)=O)[C@H](O)[C@H]1NS([O-])(=O)=O
  • InChI=1S/C31H53N3O49S8.10Na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68);;;;;;;;;;/q;10*+1/p-8/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1 Зелена квачицаДа
  • Key:XEKSTYNIJLDDAZ-JASSWCPGSA-F Зелена квачицаДа

Fondaparinuks je organsko jedinjenje, koje sadrži 31 atom ugljenika i ima molekulsku masu od 1730,097 Da.[1][2][3][4][5][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]

Osobine

[уреди | уреди извор]
Osobina Vrednost
Broj akceptora vodonika 49
Broj donora vodonika 11
Broj rotacionih veza 30
Particioni koeficijent[25] (ALogP) -29,9
Rastvorljivost[26] (logS, log(mol/L)) -3,5
Polarna površina[27] (PSA, Å2) 1542,7

Reference

[уреди | уреди извор]
  1. ^ GlaxoSmithKline. Arixtra® (fondaparinux sodium) injection prescribing information. Mississauga, ON. 2010 May.
  2. ^ Eriksson BI, Bauer KA, Lassen MR, Turpie AG: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. Eriksson, B. I.; Bauer, K. A.; Lassen, M. R.; Turpie, A. G.; Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study (новембар 2001). . „Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery”. The New England Journal of Medicine. 345 (18): 1298—304. PMID 11794148. doi:10.1056/NEJMoa011100. 
  3. ^ Turpie AG, Bauer KA, Eriksson BI, Lassen MR: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 18;Turpie, A. G.; Bauer, K. A.; Eriksson, B. I.; Lassen, M. R.; PENTATHALON 2000 Study Steering Committee (мај 2002). . „Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A randomised double-blind trial”. Lancet (London, England). 359 (9319): 1721—6. PMID 12049860. doi:10.1016/S0140-6736(02)08648-8. 
  4. ^ Lassen MR, Bauer KA, Eriksson BI, Turpie AG: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 18;Lassen, M. R.; Bauer, K. A.; Eriksson, B. I.; Turpie, A. G.; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee (мај 2002). . „Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: A randomised double-blind comparison”. Lancet (London, England). 359 (9319): 1715—20. PMID 12049858. doi:10.1016/S0140-6736(02)08652-X. 
  5. ^ а б Bauer KA, Eriksson BI, Lassen MR, Turpie AG: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. Bauer, K. A.; Eriksson, B. I.; Lassen, M. R.; Turpie, A. G.; Steering Committee of the Pentasaccharide in Major Knee Surgery Study (новембар 2001). . „Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery”. The New England Journal of Medicine. 345 (18): 1305—10. PMID 11794149. doi:10.1056/NEJMoa011099. 
  6. ^ Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M: Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. Agnelli, G.; Bergqvist, D.; Cohen, A. T.; Gallus, A. S.; Gent, M.; PEGASUS investigators (октобар 2005). . „Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery”. The British Journal of Surgery. 92 (10): 1212—20. PMID 16175516. doi:10.1002/bjs.5154. 
  7. ^ Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. Büller, H. R.; Davidson, B. L.; Decousus, H.; Gallus, A.; Gent, M.; Piovella, F.; Prins, M. H.; Raskob, G.; Segers, A. E.; Cariou, R.; Leeuwenkamp, O.; Lensing, A. W.; Matisse, Investigators (јун 2004). . „Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial”. Annals of Internal Medicine. 140 (11): 867—73. PMID 15172900. doi:10.7326/0003-4819-140-11-200406010-00007. 
  8. ^ Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. Büller, H. R.; Davidson, B. L.; Decousus, H.; Gallus, A.; Gent, M.; Piovella, F.; Prins, M. H.; Raskob, G.; Van Den Berg-Segers, A. E.; Cariou, R.; Leeuwenkamp, O.; Lensing, A. W.; Matisse, Investigators (октобар 2003). . „Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism”. The New England Journal of Medicine. 349 (18): 1695—702. PMID 14585937. doi:10.1056/NEJMoa035451. 
  9. ^ Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators; Yusuf, S.; Mehta, S. R.; Chrolavicius, S.; Afzal, R.; Pogue, J.; Granger, C. B.; Budaj, A.; Peters, R. J.; Bassand, J. P.; Wallentin, L.; Joyner, C.; Fox, K. A. (април 2006). . „Comparison of fondaparinux and enoxaparin in acute coronary syndromes”. The New England Journal of Medicine. 354 (14): 1464—76. PMID 16537663. doi:10.1056/NEJMoa055443. . Epub 2006 Mar 14.
  10. ^ Bassand JP, Richard-Lordereau I, Cadroy Y: Efficacy and safety of fondaparinux in patients with acute coronary syndromes. Expert Rev Cardiovasc Ther. Bassand, J. P.; Richard-Lordereau, I.; Cadroy, Y. (новембар 2007). . „Efficacy and safety of fondaparinux in patients with acute coronary syndromes”. Expert Review of Cardiovascular Therapy. 5 (6): 1013—26. PMID 18035917. doi:10.1586/14779072.5.6.1013. 
  11. ^ Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S: Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. FUTURA/OASIS-8 Trial Group; Steg, P. G.; Jolly, S. S.; Mehta, S. R.; Afzal, R.; Xavier, D.; Rupprecht, H. J.; López-Sendón, J. L.; Budaj, A.; Diaz, R.; Avezum, A.; Widimsky, P.; Rao, S. V.; Chrolavicius, S.; Meeks, B.; Joyner, C.; Pogue, J.; Yusuf, S. (септембар 2010). . „Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: The FUTURA/OASIS-8 randomized trial”. JAMA. 304 (12): 1339—49. PMID 20805623. doi:10.1001/jama.2010.1320. . Epub 2010 Aug 31.
  12. ^ Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA: Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. Yusuf, S.; Mehta, S. R.; Chrolavicius, S.; Afzal, R.; Pogue, J.; Granger, C. B.; Budaj, A.; Peters, R. J.; Bassand, J. P.; Wallentin, L.; Joyner, C.; Fox, K. A.; OASIS-6 Trial Group (април 2006). . „Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial”. JAMA. 295 (13): 1519—30. PMID 16537725. doi:10.1001/jama.295.13.joc60038. . Epub 2006 Mar 14.
  13. ^ Kovacs MJ: Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost. Kuo, K. H.; Kovacs, M. J. (мај 2005). . „Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux”. Thrombosis and Haemostasis. 93 (5): 999—1000. PMID 15886823. doi:10.1055/s-0037-1616573. 
  14. ^ Ortel TL: Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. Hematology Am Soc Hematol Educ Program. 2009:225-32. Ortel, T. L. (2009). . „Heparin-induced thrombocytopenia: When a low platelet count is a mandate for anticoagulation”. Hematology. American Society of Hematology. Education Program: 225—232. PMID 20008202. doi:10.1182/asheducation-2009.1.225. 
  15. ^ Moser M, Bode C: New antithrombotic agents in acute coronary syndromes. Curr Opin Cardiol. Moser, M.; Bode, C. (јул 2009). . „New antithrombotic agents in acute coronary syndromes”. Current Opinion in Cardiology. 24 (4): 313—7. PMID 19395952. doi:10.1097/HCO.0b013e32832bd350. 
  16. ^ Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI: Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. ;133(6 Suppl):141S-159S. Hirsh, J.; Bauer, K. A.; Donati, M. B.; Gould, M.; Samama, M. M.; Weitz, J. I. (2008 Jun). . „Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)”. Chest. 133 (6 Suppl): 141S—159S. PMID 18574264. doi:10.1378/chest.08-0689.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  17. ^ Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. ;133(6 Suppl):381S-453S. Geerts, W. H.; Bergqvist, D.; Pineo, G. F.; Heit, J. A.; Samama, C. M.; Lassen, M. R.; Colwell, C. W. (2008 Jun). . „Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)”. Chest. 133 (6 Suppl): 381S—453S. PMID 18574271. doi:10.1378/chest.08-0656.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  18. ^ Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ: Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. ;133(6 Suppl):454S-545S. Kearon, C.; Kahn, S. R.; Agnelli, G.; Goldhaber, S.; Raskob, G. E.; Comerota, A. J. (2008 Jun). . „Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)”. Chest. 133 (6 Suppl): 454S—545S. PMID 18574272. doi:10.1378/chest.08-0658.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  19. ^ Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Anderson, J. L.; Adams, C. D.; Antman, E. M.; Bridges, C. R.; Califf, R. M.; Casey Jr, D. E.; Chavey We, 2nd; Fesmire, F. M.; Hochman, J. S.; Levin, T. N.; Lincoff, A. M.; Peterson, E. D.; Theroux, P.; Wenger, N. K.; Wright, R. S.; Smith Jr, S. C.; Jacobs, A. K.; Adams, C. D.; Anderson, J. L.; Antman, E. M.; Halperin, J. L.; Hunt, S. A.; Krumholz, H. M.; Kushner, F. G.; Lytle, B. W.; Nishimura, R.; Ornato, J. P.; Page, R. L.; Riegel, B.; American College of Cardiology (август 2007). . „ACC/AHA 2007 guidelines for the management of patients with unstable angina/Non-ST-Elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine”. Journal of the American College of Cardiology. 50 (7): e1—e157. PMID 17692738. doi:10.1016/j.jacc.2007.02.013. .
  20. ^ Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA: Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. ;133(6 Suppl):708S-775S. Goodman, S. G.; Menon, V.; Cannon, C. P.; Steg, G.; Ohman, E. M.; Harrington, R. A. (2008 Jun). . „Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)”. Chest. 133 (6 Suppl): 708S—775S. PMID 18574277. doi:10.1378/chest.08-0665.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  21. ^ Warkentin TE, Greinacher A, Koster A, Lincoff AM: Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. ;133(6 Suppl):340S-380S. Warkentin, T. E.; Greinacher, A.; Koster, A.; Lincoff, A. M. (2008 Jun). . „Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)”. Chest. 133 (6 Suppl): 340S—380S. PMID 18574270. doi:10.1378/chest.08-0677.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  22. ^ Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG: Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. ;133(6 Suppl):670S-707S. Harrington, R. A.; Becker, R. C.; Cannon, C. P.; Gutterman, D.; Lincoff, A. M.; Popma, J. J.; Steg, G.; Guyatt, G. H.; Goodman, S. G. (2008 Jun). . „Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)”. Chest. 133 (6 Suppl): 670S—707S. PMID 18574276. doi:10.1378/chest.08-0691.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  23. ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  24. ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958. 
  25. ^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o. 
  26. ^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). . „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  27. ^ Ertl, P.; Rohde, B.; Selzer, P. (2000). . „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

Literatura

[уреди | уреди извор]

Spoljašnje veze

[уреди | уреди извор]


Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).
Преузето са „https://sr.wikipedia.org/w/index.php?title=Fondaparinuks&oldid=30641817”